ArticleDiabetes, obesity & metabolism2023

Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors: Real world evidence from the Nordic EMPRISE study.

Thomas Nyström et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.